|
End-of-day quote
Taiwan S.E.
2026-09-04
|
5-day change | 1st Jan Change | ||
| 1,310.00 TWD | -2.96% |
|
-15.21% | +209.18% |
| Aug. 31 | PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10% | MT |
| Aug. 28 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
| Market Cap | 543B 17.16B 14.77B 13.89B 12.69B 23.74B 1,620B 23.81B 164B 63.7B 831B 64.44B 63.03B 2,678B | P/E 2026 * |
49.4x | P/E 2027 * | 31.1x |
|---|---|---|---|---|---|
| Enterprise Value | 516B 16.32B 14.04B 13.21B 12.07B 22.58B 1,541B 22.64B 156B 60.59B 791B 61.29B 59.95B 2,547B | EV / Sales 2026 * |
18.2x | EV / Sales 2027 * | 12.7x |
| Free-Float |
77.98% | Yield 2026 * |
0.31% | Yield 2027 * | 0.18% |
| 1 day | -2.96% | ||
| 1 week | -15.21% | ||
| Current month | -6.09% | ||
| 1 month | +7.82% | ||
| 3 months | +54.92% | ||
| 6 months | +116.89% | ||
| Current year | +209.18% |
| 1 week | 1,280 |  | 1,645 |
| 1 month | 1,190 | | 1,645 |
| Current year | 423.7 | | 1,645 |
| 1 year | 407.92 | | 1,645 |
| 3 years | 228.27 | | 1,645 |
| 5 years | 56.05 | | 1,645 |
| 10 years | 43.54 | | 1,645 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
CEO | Chief Executive Officer | - | 2016-12-31 |
Hsueh Ling Chang
DFI | Director of Finance/CFO | - | 2015-10-13 |
Cheng Ku Huang
PSD | President | - | 2015-06-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
BRD | Director/Board Member | - | 2000-05-08 |
Ching-Leou Teng
CHM | Chairman | - | 2012-09-23 |
Cheng Ku Huang
BRD | Director/Board Member | - | 2015-05-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.96% | -15.21% | +210.71% | +370.84% | 17.16B | |
| -1.79% | -2.27% | +50.90% | +89.03% | 67.98B | |
| -2.06% | -0.18% | +41.53% | +88.17% | 64.94B | |
| -0.31% | +6.54% | -11.39% | +457.82% | 27.58B | |
| -3.00% | -2.90% | +39.40% | +9.41% | 25.74B | |
| +0.86% | +1.65% | +0.25% | -14.78% | 26.06B | |
| -1.46% | +0.42% | +24.07% | -18.70% | 20.09B | |
| -1.49% | -4.88% | -0.41% | +530.26% | 14.92B | |
| -0.20% | +8.37% | +57.87% | +159.50% | 14.62B | |
| +2.77% | +28.22% | -26.03% | +980.06% | 14.04B | |
| Average | -0.96% | +3.05% | +38.69% | +265.16% | 29.31B | |
| Weighted average by Cap. | -1.31% | +1.52% | +39.02% | +185.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.33B 895M 770M 725M 662M 1.24B 84.54B 1.24B 8.57B 3.32B 43.37B 3.36B 3.29B 140B | 40.06B 1.27B 1.09B 1.03B 936M 1.75B 120B 1.76B 12.11B 4.7B 61.34B 4.75B 4.65B 198B |
| Net income | 11.02B 348M 300M 282M 258M 482M 32.89B 483M 3.33B 1.29B 16.88B 1.31B 1.28B 54.37B | 17.69B 559M 481M 453M 414M 774M 52.79B 776M 5.35B 2.08B 27.09B 2.1B 2.05B 87.26B |
| Net Debt | -26.52B -838M -721M -679M -620M -1.16B -79.15B -1.16B -8.02B -3.11B -40.61B -3.15B -3.08B -131B | -34.73B -1.1B -945M -889M -812M -1.52B -104B -1.52B -10.5B -4.07B -53.17B -4.12B -4.03B -171B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | NT$1,310.00 | -2.96% | 3,488,695 |
| 26-09-03 | NT$1,350.00 | +3.45% | 3,196,968 |
| 26-09-02 | NT$1,305.00 | -0.38% | 3,641,430 |
| 26-09-01 | NT$1,310.00 | -6.09% | 6,395,071 |
| 26-08-31 | NT$1,395.00 | -9.71% | 10,539,537 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6446 Stock
Select your edition
All financial news and data tailored to specific country editions
